Skip to content
An Initiative of AVAC
Search
Back to Events Archive

Let’s Talk LEN: What global advances in HIV prevention mean for Black communities in the US

Thursday29August
Virtual

Groundbreaking results from the PURPOSE 1 trial conducted among cisgender Ugandan and South African women have changed the injectable PrEP global landscape. This webinar will explore the implications of these findings for US Black populations.

Moderators:

  • John Meade Jr., Senior Program Manager, Policy at AVAC & Founding Member of PrEP in Black America (PIBA)
  • Leisha McKinley-Beach, Founder & CEO, Black Public Health Academy & Founding Member of PrEP in Black America (PIBA)

Panelists:

  • Moupali Das, Executive Director, HIV Clinical Development, Gilead Sciences
  • Alex Kintu, Director, HIV Clinical Development, Gilead Sciences
  • Danielle M. Campbell, Science Equity Activist and Member, Member, PURPOSE 1 Community Accountability Group

Topic(s): Community/Advocacy, Research

Product(s): Lenacapavir

Region(s): North America

Countries: United States

Source(s): PrEP in Black America

Featured Resources

External Link

Health Impact, Budget Impact, and Price Threshold for Cost-effectiveness of Lenacapavir for HIV Pre-exposure Prophylaxis in Eastern and Southern Africa: A modelling analysis

This article from The Lancet HIV describes the use of the EMOD-HIV model to estimate the health and budget impacts and threshold price at which lenacapavir for PrEP could be cost-effective in eastern and southern Africa.
Document

The Long Wait for Long-acting HIV Prevention and Treatment Formulations

This commentary from The Lancet HIV calls on WHO, financial donors, manufacturers, and governments to take coordinated action to make long-acting HIV prevention and treatment available at scale in lower and middle income countries.
Document

PURPOSE 1 Summary

This factsheet provides a summary of the PURPOSE 1 phase III clinical trial of lenacapavir for PrEP and F/TAF for cisgender women taking place in South Africa and Uganda.
Document

Pre-Exposure Prophylaxis and Adolescent Girls and Young Women in Eastern and Southern Africa: The latest insights

Eastern and southern Africa (ESA) is the world’s most heavily HIV-impacted region, with adolescent girls and young women (AGYW) disproportionately affected. To support the scale-up of PrEP amongst AGYW in ESA, in September 2021 UNICEF and partners released the implementation brief “Improving the Quality of Pre-Exposure Prophylaxis Implementation for Adolescent Girls and Young Women in…
Document

The Lens on LEN

In late June 2024, Gilead Sciences announced an early review of the data of the PURPOSE 1 trial by an independent monitoring board, which found that injectable lenacapavir (LEN) provided as prevention was safe and highly effective against HIV. The product is being tested among 5,300 HIV-negative cisgender women ages 16-25 in Uganda and South…
External Link

Integrated Study Dashboard

This dashboard, produced under the BioPIC project, reflects all currently known activities relating to implementation research, modelling, clinical research, and landscaping for new late stage biomedical HIV PrEP options, including cabotegravir for PrEP and the dapivirine vaginal ring. To update or add any activities missing from the dashboard, or if you have questions on using…
External Link

Long-acting HIV Pre-exposure Prophylaxis (PrEP) Approaches: Recent advances, emerging technologies, and development challenges

This review from Expert Opinion on Drug Delivery discusses the current state of the long acting PrEP field, recent advances, and emerging technologies, including ARV prodrug modifications and new drug delivery systems. Technological challenges, knowledge gaps, preclinical testing considerations, and future directions important in the context of clinical translation and implementation of long acting HIV…
External Link

The Years Ahead in Biomedical HIV Prevention Research

This graphic shows the updated status of large-scale prevention trials through 2024.
External Link

The Future of ARV-Based Prevention and More

The pipeline of non-vaccine HIV prevention products includes oral pills, vaginal rings, vaginal and rectal gels, vaginal films, long-acting injectable antiretrovirals and more. Also pictured are the range of multipurpose prevention technologies in development that aim to reduce the risk of HIV and STIs and/or provide effective contraception for women.